AI-generated summary
This review summarises recent findings on photobiomodulation using near-infrared light to treat cerebrovascular diseases such as stroke, focusing on its potential to restore nitric oxide signalling. The authors report that animal studies showed improved stroke outcomes with near-infrared-II light, while clinical trials using the near-infrared-I window have not yet shown a benefit for ischaemic stroke. The authors also discuss its potential use for other neurological conditions.
- Who or what was studied
- unclear
- Wavelengths
- 630, 900, 1000, 1700 nm
- Limits stated in the abstract
- The stroke benefits described come from animal models, and the authors note that clinical trials in the near-infrared-I window have not yet demonstrated a benefit for ischaemic stroke.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 630-900 nm, 1000-1700 nm
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Near-infrared, Nitric oxide, Stroke, Traumatic brain injury, Cerebral blood flow, Penetration depth, Brain injury. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.